Literature DB >> 17066486

Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.

James D Lewis1, Rita Schinnar, Warren B Bilker, Xingmei Wang, Brian L Strom.   

Abstract

BACKGROUND: The Health Improvement Network (THIN) is a new medical records database that contains records from general practices some of which have or continue to participate in the General Practice Research Database (GPRD) and others that never participated in GPRD. We sought to replicate in THIN well-established associations from the medical literature and to compare results from the GPRD practices to the non-GPRD practices within THIN.
METHODS: Using THIN data from 1986-2003, we conducted case-control studies of associations between diseases (e.g., hypertension and stroke) and between diseases and drugs (e.g., aspirin and colon cancer). Conditional logistic regression was used to calculate odds ratios adjusted for potential confounders. Differences between GPRD and non-GPRD practices were assessed by testing for a statistical interaction by practice type in each outcome-exposure association.
RESULTS: We observed the expected positive associations (p < 0.05) of stroke with hypertension and diabetes mellitus; of myocardial infarction with hypertension, hypercholesterolemia, obesity, and smoking; and of peptic ulcer disease with aspirin, NSAIDs, and potassium. We observed the expected negative associations (p < 0.05) of colorectal cancer with aspirin, NSAIDs, and cox-2 inhibitors. The expected protective effect of aspirin use for myocardial infarction was not observed. In all cases, the results obtained from the GPRD practices were similar to the results obtained from the non-GPRD practices, only being statistically different for the associations of myocardial infarction with diabetes and aspirin use.
CONCLUSIONS: THIN data that are collected outside of the GPRD appear as valid as the data collected as part of the GPRD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17066486     DOI: 10.1002/pds.1335

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  229 in total

1.  Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study.

Authors:  K A Forde; K Haynes; A B Troxel; S Trooskin; M T Osterman; S E Kimmel; J D Lewis; V Lo Re
Journal:  J Viral Hepat       Date:  2011-11-13       Impact factor: 3.728

2.  Quality of prescribing in care homes and the community in England and Wales.

Authors:  Sunil M Shah; Iain M Carey; Tess Harris; Stephen DeWilde; Derek G Cook
Journal:  Br J Gen Pract       Date:  2012-05       Impact factor: 5.386

3.  Managing data quality for a drug safety surveillance system.

Authors:  Abraham G Hartzema; Christian G Reich; Patrick B Ryan; Paul E Stang; David Madigan; Emily Welebob; J Marc Overhage
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

4.  Hormonal contraception is not associated with increased risk for seizures in the general population: results from a cohort study using The Health Improvement Network.

Authors:  Christoph Patrick Beier; Luis A García Rodríguez; María E Sáez; David Gaist; Antonio González-Pérez
Journal:  Eur J Clin Pharmacol       Date:  2018-05-31       Impact factor: 2.953

5.  Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease.

Authors:  Goodarz Danaei; Luis A García Rodríguez; Oscar Fernández Cantero; Roger Logan; Miguel A Hernán
Journal:  Stat Methods Med Res       Date:  2011-10-19       Impact factor: 3.021

6.  Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection.

Authors:  Vincent Lo Re; Kevin Haynes; Kimberly A Forde; A Russell Localio; Rita Schinnar; James D Lewis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-09       Impact factor: 2.890

7.  An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance.

Authors:  Xiaofeng Zhou; Sundaresan Murugesan; Harshvinder Bhullar; Qing Liu; Bing Cai; Chuck Wentworth; Andrew Bate
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

8.  Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study.

Authors:  Kashif Jafri; Christie M Bartels; Daniel Shin; Joel M Gelfand; Alexis Ogdie
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-11-28       Impact factor: 4.794

9.  Prevalence and treatment patterns of psoriatic arthritis in the UK.

Authors:  Alexis Ogdie; Sinéad Langan; Thorvardur Love; Kevin Haynes; Daniel Shin; Nicole Seminara; Nehal N Mehta; Andrea Troxel; Hyon Choi; Joel M Gelfand
Journal:  Rheumatology (Oxford)       Date:  2012-12-07       Impact factor: 7.580

10.  The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study.

Authors:  Ada Man; Yanyan Zhu; Yuqing Zhang; Maureen Dubreuil; Young Hee Rho; Christine Peloquin; Robert W Simms; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2012-08-17       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.